Skip to content

Lyora Therapeutics

6 viewers · 30d

Total raised

$525K

1 filing since 2025 · latest Options filed

Cumulative raised
LAST ROUND
Options · $525K
ROUNDS
1
INVESTORS
4
FOUNDED
2024
HQ
Belmont, MA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
6

AI overview

Updated

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing groundbreaking therapies specifically for chronic rhinosinusitis (CRS), a prevalent inflammatory condition affecting the nasal passages and sinuses. By leveraging innovative technologies, Lyra aims to provide effective solutions for CRS patients who often endure ineffective treatments and potentially invasive surgeries.

What sets it apart

Lyra stands out through its proprietary XTreo technology platform, which enables sustained, localized medication delivery to ENT tissues without the need for invasive procedures.

Funding history

1 round
OptionsFeb 25, 2025
Form D
+$525K$525K total

Latest SEC filings

via EDGAR · CIK 0002058969
Form D · Feb 25, 2025View on EDGAR

Products

1 tracked

LYR-210

Therapeutic Implant

LYR-210 is a bioresorbable nasal implant specifically designed to deliver continuous anti-inflammatory medication for up to six months directly to the sinonasal passages. This innovative solution targets chronic rhinosinusitis patients who have not yet undergone sinus surgery, aiming to alleviate their symptoms effectively without requiring invasive interventions.

  • Bioresorbable implant
  • Delivers medication for up to 6 months
  • Non-invasive application
  • Direct delivery to sinonasal passages

Links

WebsiteSEC EDGAR filings